Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Building and validating a prognostic index for biomarker studies.

Xuelin Huang1, Swati Biswas, Elihu H Estey

  • 1Department of Biostatistics & Applied Mathematics, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA.

Cancer Biomarkers : Section a of Disease Markers
|December 29, 2006
PubMed
Summary

This study introduces a new method for selecting and validating prognostic biomarkers in cancer research. The proposed prognostic index effectively combines multiple markers to predict patient outcomes, even with limited predictive individual markers.

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results.

Nature cancer·2026
Same author

Statistical innovations in clinical trial design with a focus on drug combinations, factorials, and other multiple therapy issues.

The journal of prevention of Alzheimer's disease·2025
Same author

Adaptive Bayesian Clinical Trials: The Past, Present, and Future of Clinical Research.

Journal of clinical medicine·2025
Same author

Annual Versus Biennial Mammographic Screening.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Area of Science:

  • Oncology
  • Biostatistics
  • Genetics

Background:

  • Identifying prognostic biomarkers is crucial for personalized cancer treatment and predicting recurrence risk.
  • Many studies include numerous biomarkers, but only a few are truly prognostic, leading to challenges in selection and validation.

Purpose of the Study:

  • To propose and validate a method for building a prognostic index using potentially many molecular and genetic markers.
  • To demonstrate the effectiveness of the proposed method in controlling false-positive rates and maintaining statistical power.

Main Methods:

  • The study proposes a novel method for the selection and validation of prognostic biomarkers.
  • A simulation approach was used to evaluate the performance of the proposed prognostic index construction method.

Related Experiment Videos

Main Results:

  • The proposed method effectively controls the false-positive rate in biomarker selection.
  • The developed prognostic index demonstrates significant power by combining multiple prognostic biomarkers, even when individual markers have limited predictive value.

Conclusions:

  • The validated prognostic index offers a powerful tool for integrating multiple biomarkers to predict cancer recurrence and treatment response.
  • This approach enhances the utility of large-scale biomarker studies in clinical oncology.